Vaderis Therapeutics AG is a clinical stage biotech focusing on treatment of rare diseases caused by vascular malformations. The company was founded in 2019 in Basel, Switzerland, and closed a Series A investment of CHF 18.1 Mio in 2020, and a Series B investment of USD 152 million in August 2026.
- https://vaderis.com/
- +41 79 863 52 07
- Send an email
- Azmi Nabulsi, CEO